Tumores Gastrintestinais

Revisão sistemática e meta-análise de não inferioridade de estudos randomizados fases II/III | Terapia baseada em S-1 vs. 5-fluorouracila ou terapia baseada em capecitabina no tratamento de pacientes com câncer colorretal metastático.

15 Mar, 2022 | 12:48h

Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer – European Journal of Cancer

---

Assinaturas genéticas no câncer hepatobiliar.

14 Mar, 2022 | 13:25h

Mutational signatures and processes in hepatobiliary cancers – Nature Reviews Gastroenterology & Hepatology (se o acesso a este link for pago, tente este)

 

Comentário no Twitter

Appeared online this week in @NatRevGastroHep 🧵
"Mutational signatures and processes in hepatobiliary cancers" a #Review article
Read here 👉🏾https://t.co/fUcaZ81BSA
Attached Figure: a clinicopathological and molecular overview of hepatobiliary cancers pic.twitter.com/d6MVAFu0J1

— Nature Reviews Gastroenterology & Hepatology (@NatRevGastroHep) March 11, 2022

 

---

Viabilidade da alta hospitalar em 72 horas após grande cirurgia colorretal: lições aprendidas após 5 anos de experiência institucional com o protocolo ERAS.

10 Mar, 2022 | 15:27h

Feasibility of discharge within 72 hours of major colorectal surgery: lessons learned after 5 years of institutional experience with the ERAS protocol – BJS Open

Conteúdos relacionados:

ERAS Guidelines for Perioperative Care in Elective Colorectal Surgery

Review: Enhanced Recovery After Surgery in Emergency Colorectal Surgery

Clinical Practice Guidelines for Enhanced Recovery After Colon and Rectal Surgery From the American Society of Colon and Rectal Surgeons and Society of American Gastrointestinal and Endoscopic Surgeons

 

Comentário no Twitter

A five year #retrospective #cohort study explored link between early post-op discharge and #ERAS (n=965)

-> adherence to >80% ERAS components associated with early discharge. Long operations, drains, and complications assoc w/longer stays.https://t.co/2nXBrKbg5D#SoMe4Surgery pic.twitter.com/h5P4YFC8zh

— BJS Open (@BjsOpen) March 2, 2022

 

---

Estudo randomizado | S-1 com oxaliplatina é não inferior a fluorouracil, leucovorina com oxaliplatina como quimioterapia perioperatória para câncer gástrico ressecável e localmente avançado.

9 Mar, 2022 | 13:35h

Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial – JAMA Network Open

 

Comentário no Twitter

In this RCT, S-1 plus oxaliplatin was noninferior to fluorouracil, leucovorin plus oxaliplatin as perioperative chemotherapy regimen for patients with locally advanced gastric cancer. https://t.co/W6fc1YcSBd

— JAMA Network Open (@JAMANetworkOpen) February 28, 2022

 

---

M-A | Características clínicas, vigilância, alocação de tratamentos e desfechos do carcinoma hepatocelular relacionado a doença hepática gordurosa não alcoólica.

8 Mar, 2022 | 17:15h

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis – The Lancet Oncology

 

Comentário do autor no Twitter (fio – clique para saber mais)

In this global study of NAFLD-related HCC, we determine:

1.Prevalence
2.Clinical characteristics
3.% cirrhosis
4.Surveillance
5.Treatment allocation
6.Outcomes#LiverCancerSIG #Livertwitter

Free to read @TheLancetOncol https://t.co/vwAeicpWxq

1/n pic.twitter.com/gM1BHVSwXl

— Daniel Huang (@DrHuangDQ) March 4, 2022

 

---

Estudo randomizado aberto de fase 2 | Radioterapia estereotática com pembrolizumabe e trametinibe vs. radioterapia estereotática com gencitabina para câncer pancreático localmente recidivante após ressecção cirúrgica.

8 Mar, 2022 | 15:25h

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)

---

Riscos de outros tipos de câncer, além dos cânceres de mama e de ovário, associados às variantes patogênicas BRCA1 e BRCA2.

3 Mar, 2022 | 15:45h

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants – Journal of Clinical Oncology

Comentário: Faulty BRCA genes linked to prostate and pancreatic cancers – University of Cambridge

---

Novas estratégias de tratamento para tumores estromais gastrintestinais em estágio avançado.

28 Fev, 2022 | 13:30h

New treatment strategies for advanced-stage gastrointestinal stromal tumours – Nature Reviews Clinical Oncology (se o acesso a este link for pago, tente este)

 

Comentário no Twitter

In a Review now live online, @LRberyllium, @HKhosroyani, Jason D. Kent & Michael Heinrich from the @GistLab at @OHSUKnight discuss 'New treatment strategies for advanced-stage gastrointestinal stromal tumours: https://t.co/pJ0cMuvUMG #scmsm #stcsm #esocsm #CRCSM pic.twitter.com/lMtjkAcJUZ

— NatureRevClinOncol (@NatRevClinOncol) February 25, 2022

 

---

Principais avanços de 2021 sobre câncer esofágico/de junção gastroesofágica.

25 Fev, 2022 | 14:09h

Top advances in esophageal/gastroesophageal junction cancers in 2021 – Cancer

---

Diretriz baseada em evidências para vigilância de pacientes após tratamento curativo de câncer colônico e retal.

25 Fev, 2022 | 14:08h

An Evidence-Based Guideline for Surveillance of Patients after Curative Treatment for Colon and Rectal Cancer – Current Oncology

---